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BACKGROUND: Only 40–70% of metastatic colorectal cancers (mCRCs) with wild-type (WT) KRAS oncogene respond to
anti-epidermal growth factor receptor (anti-EGFR) antibody treatment. EGFR amplification has been suggested as an additional
marker to predict the response. However, improved methods for bringing the EGFR analysis into routine laboratory are needed.
METHODS: The material consisted of 80 patients with mCRC, 54 of them receiving anti-EGFR therapy. EGFR gene copy number
(GCN) was analysed by automated silver in situ hybridisation (SISH). Immunohistochemical EGFR protein analysis was used to guide
SISH assessment.
RESULTS: Clinical benefit was seen in 73% of high (X4.0) EGFR GCN patients, in comparison with 59% of KRAS WT patients. Only
20% of low EGFR GCN patients responded to therapy. A high EGFR GCN number associated with longer progression-free survival
(Po0.0001) and overall survival (P¼0.004). Together with KRAS analysis, EGFR GCN identified the responsive patients to anti-EGFR
therapy more accurately than either test alone. The clinical benefit rate of KRAS WT/high EGFR GCN tumours was 82%.
CONCLUSION: Our results show that automated EGFR SISH, in combination with KRAS mutation analysis, can be a useful and easily
applicable technique in routine diagnostic practise for selecting patients for anti-EGFR therapy.
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The major prognostic determinant for patients with advanced
colorectal cancer (CRC) with non-resectable metastases is the
response to systemic therapy (Cunningham et al, 2010). For part of
these patients, recent advances, including anti-epidermal growth
factor receptor (EGFR) therapy have added clinical benefit and
extended the median survival time (Cunningham et al, 2004;
Douillard et al, 2010; Grothey, 2010; Peeters et al, 2010).
Tumours harbouring activating mutations of KRAS, a signalling
molecule downstream of EGFR, do no benefit from the anti-EGFR
monoclonal antibodies cetuximab and panitumumab (Linardou
et al, 2008; Allegra et al, 2009). In KRAS wild-type (WT) patients,
on the other hand, the addition of cetuximab to cytotoxic
treatment in first line improves the response rates with 16–24%
compared with cytotoxic therapy alone. However, about 40% of the
previously untreated (Bokemeyer et al, 2009; Chang et al, 2009;
Van Cutsem et al, 2009) and about 60–70% of the previously
treated (Moroni et al, 2005; Lievre et al, 2006, 2008; Chang et al,
2009) KRAS WT patients do not respond to anti-EGFR treatment
combined with chemotherapy. Consequently, there is a need for
predictive markers among the KRAS WT patients. Changes in
molecules downstream of EGFR, in particular BRAF gene
mutations, PIK3CA mutations and loss of expression of the PTEN
tumour-suppressor protein appear to associate with resistance to
anti-EGFR treatment (Laurent-Puig et al, 2009; Siena et al, 2009).
However, even the combination of these is likely to identify only a
minority of non-responsive KRAS WT patients (Laurent-Puig et al,
2009).
Unlike the EGFR protein expression level assessed by immuno-
histochemistry (IHC) (Cunningham et al, 2004; Saltz et al, 2004;
Chung et al, 2005), an increased EGFR gene copy number (GCN)
has been associated with a favourable response to anti-EGFR
therapy among KRAS WT patients (Moroni et al, 2005; Lievre et al,
2006; Sartore-Bianchi et al, 2007; Cappuzzo et al, 2008).
Fluorescence in situ hybridisation (FISH) technique has been used
in most previous studies (Moroni et al, 2005; Sartore-Bianchi et al,
2007; Cappuzzo et al, 2008; Personeni et al, 2008; Scartozzi et al,
2009). The FISH results are challenging to interpret and the lack of
standardisation of analytical methods and scoring systems may
partly explain why the EGFR GCN evaluation has not been
incorporated into the clinical practice yet (Martin et al, 2009).
Silver in situ hybridisation (SISH) is a technique that can be
applied to automated detection of EGFR GCN and chromosome 7
(Chr-7) number. SISH-based EGFR GCN can be easily performed,
because it can be analysed by conventional bright field light
microscopy. In addition, the chromogen of SISH is very stable
unlike fluorochromes in FISH. The aim of this study hwas to
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sevaluate the predictive value of EGFR GCN and Chr-7 number
assessed by SISH from areas with highest IHC reactivity in patients
with metastatic or locally advanced CRC treated with anti-
EGFR monoclonal antibody therapy. The correlation between
EGFR GCN and EGFR protein expression, as determined by
IHC, was also evaluated, since previous reports have been conflicting
(Shia et al, 2005; Spindler et al, 2006; Frattini et al,2 0 0 7 ;H e m m i n g s
et al, 2009).
PATIENTS AND METHODS
Patients
This retrospective study comprises a series of 80 metastatic or
locally advanced CRC patients, 62 of whom were treated with
anti-EGFR therapy at the Turku University Hospital. In all, 50% of
the patients had metastatic disease at the time of diagnosis. The
median age of the patients at diagnosis was 60 years (range,
34–73). Patient characteristics and treatments are presented in
Table 1. Ten of the treated patients had a mutation in the KRAS
gene, as the anti-EGFR therapy was administered before establish-
ment of the predictive value of KRAS testing. The treatment
response could be reliably evaluated for 54 out of 62 (87%)
of treated patients. Of those, 25 KRAS WT patients received
cetuximab or panitumumab either as single therapy or irinotecan
combination therapy in a chemorefractory phase of the disease
(Xthird line therapy). The response to anti-EGFR treatment
was evaluated by computed tomography or magnetic resonance
imaging according to the Response Evaluation Criteria in
Solid Tumours (Eisenhauer et al, 2009). The study was conducted
in accordance with the Declaration of Helsinki. The clinical data
were retrieved and histological samples collected and analysed
with the endorsement of the National Authority for Medico-Legal
Affairs.
Procedures
Formalin-fixed, paraffin-embedded samples with at least 30% of
CRC cells were selected and analysed for KRAS point mutations
within codons 12 and 13 with the DxS K-RAS mutation kit (DxS
Ltd, Manchester, UK).
In all, 3mm sections were stained with two monoclonal
antibodies against EGFR (VentanaMedical Systems/Roche Diag-
nostics, Tucson, AZ, USA). EGFR (clone 3C6) mAb is directed
against the extracellular domain of human EGFR, and EGFR (clone
5B7) mAb against the internal domain of human EGFR. All 80
tumour specimens were stained with the 5B7 anti-EGFR antibody
and 74 tumour samples with the 3C6 anti-EGFR antibody.
Stainings were performed with BenchMark XT (Ventana/Roche)
using ultraVIEW Universal DAB Detection Kit (Ventana/Roche).
EGFR IHC was scored independently by three observers (OC, JS,
and ML) blinded of the clinical information. Three scoring
parameters were recorded: the highest (covering at least 10% of
the tumour area), the most common staining intensity, and the
localisation of staining (membranous, cytoplasmic or both). Four
categories of staining intensity were used: 0 (negative), þ (weak),
þþ(moderate), and þþþ(strong, similar to the intensity of
the epidermal basal layer). In cases of discordance, a consensus
score was used.
EGFR gene was detected from 5mm sections with EGFR DNA
Probe (Ventana/Roche) and Chr-7 from parallel sections with
Chr-7 oligonucleotide Probe (Ventana/Roche). SISH was per-
formed with the BenchMark XT using ultraVIEW SISH Detection
Kit (Ventana/Roche). From each tumour EGFR GCN (number of
copies of gene per cell) and Chr-7 number (number of copies of
chromosome per cell) were analysed by two observers (ML and JS)
from the area of highest IHC reactivity. Forty tumour cells with the
highest number of copies were analysed from the EGFR SISH
slides. In addition to the average EGFR GCN and Chr-7 number,
EGFR/Chr-7 copy number ratio was assessed.
Table 1 Baseline characteristics of patients who underwent SISH for
EGFR and chromosome 7 and analysis of KRAS gene mutational status
(a) and the subgroup of these patients that received anti-EGFR therapy
with evaluable treatment response and sufficient follow up data (b)
(a) Eligible
patients for
KRAS mutational
status analysis, EGFR
and chromosome
7 SISH analysis
(n¼80)
(b) Patients
treated with
anti-EGFR therapy
(n¼54)
KRAS WT
and MT,
n¼80
KRAS
WT,
n¼44
KRAS
MT,
n¼10
n (%) n (%) n (%)
Sex
Female 34 (42) 18 (40.9) 6 (60)
Male 46 (58) 26 (59.1) 4 (40)
Site of primary tumour
Colon 51 (63.8) 32 (72.7) 6 (60)
Rectum 28 (35) 12 (27.3) 4 (40)
Unknown 1 (1.2)
Metastatic sites
Single 28 (35) 19 (43.2) 2 (20)
Multiple 52 (65) 25 (56.8) 8 (80)
Tumour differentiation grade
Grade 1 11 (13.8) 6 (13.6) 1 (10)
Grade 2 50 (62.5) 28 (63.7) 6 (60)
Grade 3 13 (16.2) 6 (13.6) 2 (20)
Unknown 6 (7.5) 4 (9.1) 1 (10)
Follow-up data of the patients
Alive with disease 16 (20) 10 (22.7) —
Alive and free of disease 5 (6.2) 1 (2.3) —
Died of disease 59 (73.8) 33 (75) 10 (100)
KRAS mutational status
KRAS WT 54 (67.5) 44 (100) —
KRAS MT 24 (30) — 10 (100)
Not evaluable 2 (2.5) — —
Anti-EGFR treatment
Cetuximab 51 (63.8) 35 (79.5) 10 (100)
Panitumumab 10 (12.5) 8 (18.2) —
Both 1 (1.2) 1 (2.3) —
None 18 (22.5) — —
Line of therapy
First 8 (12.9) 5 (11.4) 1 (10)
Second 14 (22.6) 12 (27.3) —
Third or more 40 (64.5) 27 (61.3) 9 (90)
Anti-EGFR combination therapy
Anti-EGFR
combined to IRI
46 (74.2) 32 (72.7) 9 (90)
Anti-EGFR
combined to OXA
10 (16.1) 8 (18.2) 1 (10)
Anti-EGFR
combined to CAP
2 (3.2) 1 (2.3) —
Single treatment 4 (6.5) 3 (6.8) —
Abbreviations: CAP¼capecitabine; EGFR¼epidermal growth factor receptor; IRI¼irinotecan;
MT¼mutated; OXA¼oxaliplatin; SISH¼silver in situ hybridization; WT¼wild type.
EGFR GCN (SISH) predicts outcome in anti-EGFR treated CRC
AA ˚lgars et al
256
British Journal of Cancer (2011) 105(2), 255–262 & 2011 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sFISH analysis with Vysis EGFR/CEP 7 FISH Probe Kit (Abbott
Molecular Inc., Des Plaines, IL, USA) was performed on nine
samples selected based on EGFR SISH results (three samples with
clusters, three samples with more than four copies, and three
samples with normal two copies), using standard protocols.
Statistical analysis
Statistical analyses were performed with the SAS 9.2 and Enterprise
Guide 4.2 programs (SAS Institute Inc., Cary, NC, USA). Frequency
table data were analysed with the w
2-test or Fisher’s exact test.
Spearman correlation coefficients were calculated when correla-
tions were analysed. The optimal cut-off values for EGFR GCN and
Chr-7 number were defined with the receiver operating character-
istic (ROC) analysis generated on response to treatment (clinical
benefit vs progressive disease (PD)). Kaplan–Meier and log-rank
tests as well as Cox proportional hazards regression model were
used for univariate survival analysis. When analysing progression-
free survival (PFS), the survival time was calculated from the onset
of anti-EGFR treatment until disease progression. When evaluating
the overall survival (OS), the survival time was calculated from the
onset of anti-EGFR therapy until death. Multivariate survival
analysis was carried out by using Cox’s proportional hazards
regression model. All statistical tests were two-sided. P-values
o0.05 were considered to be statistically significant.
RESULTS
EGFR IHC and EGFR and Chr-7 SISH analysis
Owing to the chromogenic detection method of EGFR GCN and
EGFR protein, it was possible to assess both parameters from
identical tumour areas and to compare the results. The EGFR
protein expression levels and subcellular localisations were
examined by two different anti-EGFR antibodies: clone 5B7 against
the intracellular domain and clone 3C6 against the extracellular
domain, hereafter referred to as intracellular and extracellular
domain antibodies, respectively. In general, the intensity and
subcellular localisation of IHC reactivity showed considerable
intratumoural variation with both antibodies (Figure 1). Therefore,
the following parameters were determined: localisation, highest,
and most common intensity. The results obtained with the two
different antibodies statistically significantly correlated with each
other disregarding the parameter used (Po0.0001, Spearman). The
most intense areas were scored as moderate (þþ) in a majority
of the tumours, while only one-tenth of the tumours showed areas
of strong intensity (þþþ). The most common EGFR staining
intensity was low (þ) with both antibodies. The frequencies of
these parameters are presented in Table 2.
The marked variation in EGFR expression as analysed by IHC
might reflect an intratumoural variation in the EGFR GCN.
Therefore, we assessed the EGFR GCN and Chr-7 number from
areas with strongest EGFR staining. The mean EGFR GCN was 5.5
(median 5.5) and the mean Chr-7 number 5.4 (median 5.3).
The optimal cut-off values for EGFR GCN and Chr-7 number as
determined with ROC curves were 4.0 (sensitivity 86%, specificity
72%, AUC 83%) and 4.5 (sensitivity 84%, specificity 79%, AUC
85%), respectively. The optimal cut-off value for EGFR GCN was in
addition defined with ROC analysis for the selected patients with
chemorefractory disease who received anti-EGFR therapy±irino-
tecan in Xthird line. The cut-off value proved to be 4.0 (sensitivity
89%, specificity 67%, AUC 84%) in this patient group as well. In
all, 51 tumours out of 80 (64%) had an EGFR GCN above cut-off
value determined by ROC-analysis (X4.0). The EGFR GCN
analysis by SISH could not be performed in 2 out of 80 (2.5%)
of the cases. Chr-7 number was above the cut-off value (X4.5) in
48 out of 80 (60%) of the tumours. The highest EGFR/Chr-7 GCN
ratio was 2.8 (mean 1.05, median 1.0). The EGFR FISH results from
nine selected tumours correlated with the SISH results.
An increased EGFR GCN and Chr-7 number correlated
positively with EGFR IHC analysed by the intracellular domain
antibody (Spearman, P¼0.01 for both) (Table 3). The correlation
remained statistically significant when the staining intensity (IHC)
was dichotomised into categories 0 and þ vs þþand þþþ.
A significant correlation between extracellular domain antibody
reactivity and an increased Chr-7 number was seen (Spearman,
P¼0.04), whereas, no correlation was observed between extra-
cellular domain antibody reactivity and EGFR GCN. The sub-
cellular localisation of the EGFR IHC (intracellular and
extracellular domain antibodies) did not correlate with EGFR
GCN or the Chr-7 number. KRAS mutational status did not
correlate either with EGFR and Chr-7 SISH or EGFR IHC results.
EGFR SISH and treatment response
In all, 73% of high EGFR GCN (X4.0) patients showed clinical
benefit (complete response (CR)þpartial response (PR)þstable
disease (SD)) from anti-EGFR therapy, whereas only 20% of low
EGFR GCN (o4.0) benefited from treatment (Figure 2). In
comparison, 59% of the KRAS WT patients showed clinical
benefit. In KRAS WT patients with a high EGFR GCN (X4.0),
clinical benefit was more frequent (82%) than in the overall KRAS
WT or high EGFR GCN population. A high Chr-7 number (X4.5)
was also significantly associated with an improved anti-EGFR
treatment response among KRAS WT patients.
Anti-EGFR drugs were given as first-line treatment to five KRAS
WT patients, four of which (80%) showed an objective response.
Interestingly, all four patients had an EGFR GCN X4.0. The fifth
KRAS WT patient had an EGFR GCN o4.0 and progressed during
therapy. We performed the statistical analyses separately by
excluding the five KRAS WT patients who received anti-EGFR
therapy as first-line treatment. Improved response rates were still
seen in the group of KRAS WT patients with a high EGFR GCN
(X4.0); an objective response was observed in 25% (6 out of 24),
SD in 54% (13 out of 24) and PD in 21% (5 out of 24) of the
patients. In the patients with a low EGFR GCN (o4.0), progressive
disease was seen in 80% (12 out of 15) of the cases (Fisher’s exact
test, P¼0.002).
In addition, the statistical analyses were performed separately
for the KRAS WT chemorefractory CRC patients who received
anti-EGFR therapy in Xthird line, either as single drug therapy
(n¼3) or in combination with irinotecan (n¼22). In all, 84% of
the patients with a high EGFR GCN (X4.0) achieved either a SD or
PR. In contrast, the clinical benefit rate was only 33% for the
patients with a low EGFR GCN (o4.0) (Fisher’s exact test,
P¼0.03). Stable disease was the best response recorded for 13 out
of 25 patients in this selected patient group and of those 69%
(9 out of 13) had a prolonged SD (X24 weeks). When excluding
the patients with SD duration of o24 weeks from the analysis a
significant association between treatment response and EGFR GCN
status was still seen in a similar fashion (Fisher’s exact test,
P¼0.02).
EGFR SISH and survival
In the entire treated population, the EGFR GCN associated
significantly with an improved PFS when using the ROC-curve
based cut-off value of 4.0. Interestingly, the PFS time of the KRAS
WT patients with EGFR GCN o4.0 was indifferent from those with
KRAS mutation. The median PFS time of KRAS WT/EGFR GCN
X4.0 was 35 weeks compared with only 12 weeks of the KRAS WT/
EGFR GCN o4.0 patients. The PFS remained significantly longer
in the KRAS WT patient population with a high EGFR GCN when
analysing only the patients treated with anti-EGFR therapy in
second line or more (log-rank test, Po0.0001). Furthermore, in the
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panitumumab or cetuximab±irinotecan in Xthird line (n¼25),
the median PFS time was significantly longer in the KRAS WT/
EGFR GCN X4.0 patients than in the KRAS WT/EGFR GCN o4.0
patients; 35 vs 10 weeks (log-rank test, P¼0.003; Cox test,
P¼0.007, HR: 0.22, 95% CI: 0.08–0.66). Similar results were
obtained when excluding the patients with a short SD duration
(o24 weeks) from the analysis (log-rank test, P¼0.0008; Cox test,
P¼0.003, HR: 0.15, 95% CI: 0.04–0.53; PFS time 42 vs 8 weeks).
Other factors associated with improved PFS in the entire group of
A
C
B
D
E F
GH
Figure 1 Epidermal growth factor receptor immunohistochemistry, EGFR, and Chr-7 SISH in colorectal cancer and normal colorectal tissues. Epidermal
growth factor receptor IHC with clones 5B7 (A) and 3C6 (B). EGFR SISH revealing gene clusters (C) and the corresponding Chr-7 SISH (D). EGFR SISH
with GCN X4.0 (E) and the corresponding Chr-7 SISH (F). EGFR SISH (G) and Chr-7 SISH (H) in normal colorectal tissue. Scale bar 0.05mm (A, B),
0.02mm (C–H).
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(log-rank test, P¼0.001) and the absence of KRAS gene mutation
(log-rank test, P¼0.01).
The EGFR GCN X4.0 associated significantly with improved OS
(log-rank test, P¼0.004) in the entire treated population and in
the subgroup of KRAS WT patients (log-rank test, P¼0.001). The
Chr-7 number did not associate with OS. The median OS time for
patients with KRAS WT/EGFR GCN X4.0 tumours was 85 weeks
compared with 19 weeks for those with KRAS WT/EGFR GCN
below the cut-off value. When excluding the patients treated with
anti-EGFR therapy in first line the OS was still significantly higher
in the patients with an EGFR GCN X4.0 (log-rank test, P¼0.001).
In the selected patient group treated with anti-EGFR antibodies
±irinotecan in Xthird line an EGFR GCN X4.0 predicted a
prolonged OS as well; 74 vs 16 weeks in the group of patients with a
low EGFR GCN (log-rank test, P¼0.0005; Cox test, P¼0.003, HR:
0.13, 95% CI: 0.03–0.49). The results remained significant when
the patients with a short SD duration (o24 weeks) were excluded
from the analysis (log-rank test, P¼0.0003; Cox test, P¼0.004,
HR: 0.08, 95% CI: 0.01–0.44; PFS time 89 vs 14 weeks).
The responses, survival times and P-values are summarised in
Table 4, survival curves shown in Figure 3.
Multivariate survival analysis
Variables that in univariate survival analysis significantly asso-
ciated with PFS and OS in the anti-EGFR treated patient group
were included in the Cox’s multivariate analysis. The multivariate
analysis for PFS included EGFR GCN, tumour differentiation
grade, and KRAS status. EGFR GCN (P¼0.0003, HR: 0.22, 95% CI:
0.09–0.50), tumour differentiation grade (P¼0.02, HR: 0.38, 95%
CI: 0.16–0.88), and KRAS (P¼0.04, HR: 0.44, 95% CI: 0.20–0.97)
proved to be independent predictors of PFS. When the KRAS WT
patients were analysed separately, only EGFR GCN (P¼0.0003,
HR: 0.16, 95% CI: 0.06–0.43) independently predicted PFS. EGFR
GCN and tumour differentiation grade were entered for OS
analysis. Both variables predicted OS: EGFR GCN (P¼0.02, HR:
0.44, 95% CI: 0.22–0.86), tumour differentiation grade (P¼0.046,
HR: 0.43, 95% CI: 0.19–0.99). In the KRAS WT subgroup of
patients, EGFR GCN remained as a statistically significant
predictor of OS (P¼0.01, HR: 0.35, 95% CI: 0.16–0.78).
DISCUSSION
This study shows that EGFR GCN analysis, when performed from
areas with highest EGFR expression, is a highly promising method
for predicting the efficacy of anti-EGFR therapy in locally
Table 2 EGFR protein expression assessed by anti-EGFR clone 5B7
(n¼80) and anti-EGFR clone 3C6 antibodies (n¼74)
5B7 (H) 5B7 (C) 3C6 (H) 3C6 (C)
Intensity
Negative 0 (0) 11 (13.8) 9 (12.2) 31 (41.9)
1+ 19 (23.8) 50 (62.5) 20 (27.0) 37 (50.0)
2+ 53 (66.2) 19 (23.7) 38 (51.3) 6 (8.1)
3+ 8 (10) 0 (0) 7 (9.5) 0 (0)
Localisation
Membranous 23 (28.75) 11 (13.75) 24 (32.4) 11 (14.9)
Cytoplasmic 23 (28.75) 46 (57.5) 18 (24.3) 28 (37.8)
Both 34 (42.5) 12 (15) 23 (31.1) 4 (5.4)
Negative 0 (0) 11 (13.75) 9 (12.2) 31 (41.9)
Abbreviations: C¼most common staining; EGFR¼epidermal growth factor
receptor; H¼highest staining. Values are given n (%).
Table 3 Correlations of EGFR GCN (SISH), Chr-7 number (SISH), KRAS
status and EGFR protein expression (IHC), n¼74 (P-values, Spearman)
KRAS
status
EGFR GCN
(SISH)
continuous
variable
Chr-7 (SISH)
continuous
variable
Anti-EGFR clone 5B7, intensity
Highest
w NS 0.01* 0.01*
Most common
w NS NS NS
Positive or negative
a NS 0.01* 0.04*
Anti-EGFR clone 3C6, intensity
Highest
w NS NS 0.04*
Most common
w NS NS NS
Positive or negative
a NS NS NS
Localisation
5B7
y NS NS NS
3C6
y NS NS NS
EGFR GCN (SISH)
Continuous variable NS — o0.0001*
Cut-off 4.0 NS — —
Chr-7 number (SISH)
Continuous variable NS o0.0001* —
Cut-off 4.5 NS — —
Abbreviations: Chr-7¼chromosome-7; EGFR¼epidermal growth factor receptor;
GCN¼gene copy number; IHC¼immunohistochemistry; NS¼not significant;
SISH¼silver in situ hybridisation; *Significant P-value;
w0, 1+, 2+, or 3+;
aPositive
2+ or 3+, negative 0, or 1+;
yMembranous, cytoplasmic, both cytoplasmic and
membranous or negative.
AB
C
E
G H
D
F
KRAS WT, n=44
EGFR GCN   4.0, n=34 EGFR GCN < 4.0, n=20
KRAS WT and EGFR
GCN < 4.0, n=16
KRAS WT and EGFR
GCN   4.0, n=28
KRAS WT and CHr-7
  4.5, n=24
KRAS WT and CHr-7
< 4.5, n=20
KRAS MT, n=10
25% 41%
34%
27% 29%
44%
18% 36%
46%
21% 37%
42%
10%
65% 25%
81%
6% 13%
80%
5% 15%
70%
30%
PR SD PD
Figure 2 Response to anti-EGFR therapy according to EGFR GCN,
Chr-7 number, and KRAS status (A–H).
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GCN identifies the responsive patients more accurately than either
test alone. In all, 73% of patients with a high EGFR GCN (X4.0)
responded to anti-EGFR therapy, whereas a clear majority (80%) of
the patients with a low EGFR GCN were non-responders. In
comparison, 41% of the KRAS WT patients did not respond to
treatment.
Previous reports, in which chromogenic ISH (CISH) and FISH
were used to evaluate the EGFR GCN and/or Chr-7, have provided
evidence for the association of increased EGFR GCN and response
to anti-EGFR treatment. However, the predictive value of our study
seems to be better than those (Moroni et al, 2005; Lievre et al,
2006; Frattini et al, 2007; Sartore-Bianchi et al, 2007; Cappuzzo
et al, 2008; Personeni et al, 2008). What could be the explanation
for this difference? One potential factor may be the use of IHC to
guide the selection of the area for in situ analysis. The EGFR
expression showed marked intratumoural variation and therefore,
IHC was used to indicate the strongest EGFR immunoreactivity for
evaluation of the EGFR GCN and Chr-7 number by SISH. This
protocol might also explain why the EGFR GCN values were higher
in our study than in most other studies reported. Another possible
explanation could be the usage of a different EGFR probe.
However, as the FISH analyses of nine selected cases were in
concordance with SISH results, this is an unlikely explanation.
Methodological difficulties as well as reproducibility concerns
have until now prevented the usage of EGFR GCN as a predictive
marker in the clinic. The fully automated SISH technique offers
several advantages compared with manually performed FISH and
CISH. Automation improves reproducibility and compared with
FISH, SISH enables morphological identification of the analysed
tissue, which facilitates the interpretation (Dietel et al, 2007).
Several studies have indicated that EGFR IHC does not predict the
response to EGFR-targeted therapies (Cunningham et al,2 0 0 4 ;
Saltz et al, 2004; Chung et al, 2005; Cappuzzo et al, 2008). In addition,
the correlation between EGFR IHC and EGFR GCN has been poor
(Shia et al, 2005; Spindler et al, 2006; Frattini et al, 2007). Here, EGFR
IHC with intracellular domain 5B7 antibody showed a significant
correlation with the EGFR GCN and Chr-7 number. Our results may
be due to the properties of the antibodies used. The novel 5B7
antibody detects the functionally active intracellular domain of EGFR,
whereas other commercially available antibodies bind to the external
domain of the EGFR. However, also IHC scoring method may have a
role, the highest intensity assessment providing the best correlation
with EGFR GCN. Typically, a constant intensive membranous
staining correlated with areas of EGFR amplification. Consequently,
although IHC does not predict treatment response, it is important for
guiding SISH analysis, that is, indicating tumour areas with highest
degree of EGFR GCN.
Currently, patients with metastatic CRC are screened for KRAS
status and only those with KRAS WT tumours receive anti-EGFR
therapy. This selection is not absolute and about half of the patients
with KRAS WT tumours will receive the anti-EGFR monoclonal
antibodies unnecessarily. Although, BRAF, PIK3CA/PTEN, and NRAS
alterations explain a fraction of unresponsiveness (Laurent-Puig et al,
2009; Bardelli and Siena, 2010; De Roock et al, 2010) the search for
further predictive markers in this setting is feasible. Improved
predictive testing would minimise the risk of exposing the patients to
harmful side-effects caused by EGFR targeted therapies and at the
same time reduce the healthcare costs.
Our results suggest that cetuximab and panitumumab should
not be offered to KRAS WT patients with EGFR GCN o4.0.
Furthermore, according to our results, the analysis of EGFR GCN
by SISH could in certain cases be used as a substitute for KRAS
analysis, for example, when only a small biopsy of the tumour has
been taken and the amount of tumour tissue is insufficient for
KRAS analysis.
Table 4 Tumour response of patients with KRAS WT (n¼54) and KRAS MT (n¼10) metastatic or locally advanced colorectal cancer treated with
anti-EGFR therapy according to ROC curve based cut-off values of EGFR GCN and chromosome 7 number evaluated by SISH
Treatment response PFS OS
Total no.
of
patients PR SD PD
P-value
Fisher‘s
exact
test
PFS time
median
(days)
P-value
log-rank
test
P-value
Cox
test
a HR 95% CI
OS time
median
(days)
P-value
log-rank
test
P-value
Cox
test
a HR 95% CI
KRAS WT and MT patients 54
KRAS status
KRAS WT 44 11 (25) 15 (34.1) 18 (40.9) NS 151 0.01 0.01 0.40 0.20–0.84 352 0.3 0.3 0.67 0.32–1.38
KRAS MT 10 0 3 (30) 7 (70) 81 249
EGFR GCN status
EGFR GCN X4.0 34 10 (29.4) 15 (44.1) 9 (26.5) 0.0006 224 o0.0001 o0.0001 0.21 0.10–0.43 483 0.004 0.006 0.41 0.22–0.77
EGFR GCN o4.0 20 1 (5) 3 (15) 16 (80) 84 134
KRAS WT patients
EGFR GCN
X4.0 28 10 (35.7) 13 (46.4) 5 (17.9) 0.0002 244 o0.0001 o0.0001 0.17 0.07–0.39 598 0.001 0.002 0.32 0.16–0.66
o4.0 16 1 (6.2) 2 (12.5) 13 (81.3) 84 134
Chromosome 7 number
X4.5 24 9 (37.5) 10 (41.7) 5 (20.8) 0.009 214 0.2 0.2 0.67 0.35–1.29 520 0.1 0.1 0.56 0.28–1.13
o4.5 20 2 (10) 5 (25) 13 (65) 94 225
KRAS MT patients
EGFR GCN
X4.0 6 0 2 (33.3) 4 (66.7) NS 94 NS 369 NS
o4.0 4 0 1 (25) 3 (75) 77 134
Chromosome 7 number
X4.5 6 0 2 (33.3) 4 (66.7) NS 94 NS 369 NS
o4.5 4 0 1 (25) 3 (75) 77 134
Abbreviations: CI¼confidence interval; CR¼complete response; EGFR¼epidermal growth factor receptor; GCN¼gene copy number; HR¼hazards ratio; MT¼mutated;
NS¼not significant; OS¼overall survival; PD¼progressive disease; PFS¼progression-free survival; PR¼partial response; ROC¼ receiver operating characteristic; SD¼stable
disease; SISH¼silver in situ hybridisation; WT¼wild type.
aCox proportional hazards regression model. Treatment response values are given n (%). Significant P-values are
shown in bold type.
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